Exact Sciences
Biomarker-Defined Subset of Early Breast Cancer Patients Can Avoid Radiation, ASCO Data Show
The LUMINA trial showed that a molecularly defined subset of breast cancer patients over age 55 had an extremely low local recurrence rate when they omitted radiation.
ESMO Advances Biomarker Framework to Guide Cancer Therapy De-Intensification, Decision-Making
Premium
The framework, which ranks de-intensification biomarkers by evidence tiers, could give oncologists, patients, regulators, and payors a common system to guide their use.
ASCO Guideline Update Expands, Clarifies Use of Breast Cancer Adjuvant Treatment Test
The update incorporates recent evidence on test performance in different categories of patients based on age, menopausal status, and lymph node positivity.
At the AACR annual meeting, both companies shared new data on their technologies' performance in detecting early and late-stage cancers.
JP Morgan Healthcare Conference Day 3: Iovance, Elevation Oncology, Autolus, and More
Highlights of the third day included details on Iovance's regulatory progress on its TIL therapy, Elevation's seribantumab, and Precigen's UltraCAR-T therapies.